Nkarta to Participate in Evercore Healthcare Conference 2025
Tuesday, December 2, 2025 1 min read
Key Takeaway: Nkarta, Inc. will participate in the Evercore 8th Annual Healthcare Conference on December 4, 2025. The event will feature a fireside chat at 10:50 a.m. ET and will be available via a webcast. Nkarta focuses on developing engineered NK cell therapies aimed at treating autoimmune diseases, enhancing outpatient treatment accessibility.
Price reaction · baseline $1.81 (2025-12-01 close) · hit after-hours · clean, no other NKTX news in the window
day 0 close · peak
-3.9%
Market Sentiment Analysis
POSITIVE FACTORS
Nkarta is actively participating in a significant healthcare conference.
The company is advancing innovative NK cell therapies for autoimmune diseases.
A webcast of the event will be accessible to a wider audience.
Full Press Release Details
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its participation in the Evercore 8thAnnual Healthcare Conference on Thursday in Miami.
A simultaneous webcast of the event will be available on theInvestors sectionof Nkarta’s website, and a replay will be archived on the website for approximately 90 days.
About NkartaNkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for autoimmune diseases. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies, Nkarta is building a pipeline of future cell therapies engineered for deep therapeutic activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website atwww.nkartatx.com.